Antibiotics

Jason Pogue, PharmD, BCPS-ID, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.

Milena McLaughlin, PharmD, MSc, explains the best way to determine an alternative agent during a drug shortage.

Jason Gallagher, PharmD, BCPS, FCCP, FIDSA, explains how restrictions on commercial automated susceptibility testing can affect patient care.

A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.

Arjun Srinivasan, MD, shares how to focus your efforts for infectious disease outbreak investigations.

New research suggests that a vaccine designed to protect against meningitis may also protect against gonorrhea infections.

Meghan Jeffres, PharmD, explains the importance of discussing cross-reactivity among beta-lactams.

For the most challenging of microbial threats, one microbiologist is trying an old tactic in a new era.

Cases of antibiotic-resistant gonorrhea are on the rise, and the bacteria may soon become untreatable if new antibiotics and diagnostic tools are not developed.

Milena McLaughlin, PharmD, MSc, explains different strategies institutions can take to obtain antimicrobials that are on shortage.

Penn researchers find that cases of recurrent C. difficile infections are rapidly increasing, underscoring the need for new treatment options, such as fecal microbiota transplants.

Jason Pogue, PharmD, BCPS-ID, explains the limitations of the current drugs for the treatment of Pseudomonas aeruginosa infections.

In a new study conducted in a healthcare system in the Bronx, a team of healthcare providers has created a new program to cut hospital readmission rates in patients receiving outpatient IV antibiotic treatment.

Caetano Sabino, BSc, explains how photodynamic therapy can be used to challenge microbial resistance of localized infections.

Conan MacDougall, PharmD, explains what individuals should consider when it comes to adopting interventions in antibiotic stewardship programs.

Jason Gallagher, PharmD, BCPS, FCCP, FIDSA, explains how the role of antimicrobial susceptibility tests can be undermined by delays between approval of new antibiotics and the tests that will optimize their use.